🇺🇸 Fosrenol (Lanthanum Carbonate) in United States

18 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Diarrhoea — 3 reports (16.67%)
  2. Nausea — 3 reports (16.67%)
  3. Gastrointestinal Disorder — 2 reports (11.11%)
  4. Renal Disorder — 2 reports (11.11%)
  5. Unresponsive To Stimuli — 2 reports (11.11%)
  6. Vomiting — 2 reports (11.11%)
  7. Abdominal Pain — 1 report (5.56%)
  8. Alanine Aminotransferase Increased — 1 report (5.56%)
  9. Anaphylactic Reaction — 1 report (5.56%)
  10. Anti-Erythropoietin Antibody Positive — 1 report (5.56%)

Source database →

Other Nephrology approved in United States

Frequently asked questions

Is Fosrenol (Lanthanum Carbonate) approved in United States?

Fosrenol (Lanthanum Carbonate) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Fosrenol (Lanthanum Carbonate) in United States?

Shire is the originator. The local marketing authorisation holder may differ — check the official source linked above.